The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer

Allergic Conjunctivitis Clinical Trial

Official title:

The Effect of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01346371
• Other study ID #: MAC-01-11
• Status: Completed
• Phase: Phase 4
• Start date: May 2011
• Est. completion date: September 2012

Study information

• Verified date: March 2020
• Source: Minnesota Eye Consultants, P.A.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare the effect of Bepreve® with an artificial-tear eye drop on the quality of your tears.

Description:

This is a single-center, randomized, parallel group, placebo-controlled study to evaluate the effect of BEPREVE compared to a placebo eye drop on the measurement of tear film osmolarity and tear film lipid layer in patients with allergic conjunctivitis.

Subjects will be screened for this study on day one of dosing with the test article. Subjects who sign the informed consent form and who meet all inclusion/exclusion criteria will be eligible for participation in this study. They will be assigned sequentially, according to a computer generated randomization list, in a ratio of 1:1 to receive either BEPREVE™ (bepotastine besilate ophthalmic solution) 1.5% or REFRESH TEARS® Lubricant Eye Drops (1:1). Subjects will instill one drop of test article either BEPREVE™ or REFRESH TEARS® into the study eyes twice daily for a maximum of 60 days. Subjects will be seen for evaluation on Days 0, 28±3, and 56±3 following randomization.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: September 2012
• Est. primary completion date: August 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Are male or female at least 18 years of age who are diagnosed with allergic conjunctivitis.

2. Have documented positive skin prick puncture test to at least one (1) seasonal allergen (e.g., grasses, trees, weeds, or other allergens) within two (2) years of Visit 1.

3. Agree not to have any other ocular drops in study eyes within 2 days prior to the initiation of dosing with the test article or throughout the duration of the study.

4. Have a Best Corrected Visual Acuity of 20/200 or better in either eye.

5. Are willing/able to follow instructions from the study investigator and his/her staff.

6. Be willing/able to return for all required study visits, to follow instructions from the study investigator and his/her staff.

7. Are able to self-administer test article (or have a caregiver available to instill all doses of test article).

8. Have signed informed consent approved by Institutional Review Board or Independent Ethics Committee.

Exclusion Criteria:

1. Have known hypersensitivity to either BEPREVE™ or REFRESH TEARS® or to any component of the test article (including "procedural" medications such as anesthetic and/or fluorescein drops, dilating drops, etc.).

2. Have active corneal pathology noted in the study eye at the screening visit. Active corneal pathology is defined as corneal pathology that is non-stable, or greater than mild, or will compromise assessment of the safety or efficacy of treatment.

3. Have used topical, ocular, inhaled or systemic steroids within 14 days prior to screening.

4. Have a history of abuse of alcohol/drugs within six months prior to the screening visit.

5. Are pregnant or nursing/lactating.

6. Have participated in any other study of an investigational drug or device within 30 days prior to randomization.

Related Conditions & MeSH terms

• Allergic Conjunctivitis
• Conjunctivitis
• Conjunctivitis, Allergic

Intervention

Drug:
• Refresh Tears 0.5% Lubricant Eye Drops

• Bepreve 1.5% Ophthalmic Solution

Locations

Country	Name	City	State
United States	Minnesota Eye Consultants, P.A.	Minneapolis	Minnesota

Sponsors (2)

Lead Sponsor	Collaborator
Minnesota Eye Consultants, P.A.	Bausch & Lomb Incorporated

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tear Osmolarity	The TearLab Osmolarity System will be used to assess tear film osmolarity, measured in mOsms/L.	56 days after initial screening visit

External Links

•   Minnesota Eye Consultants